ZYNE Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc together with its subsidiary is a pharmaceutical company which is focused on developing and commercializing proprietary next generation synthetic cannabinoid therapeutics formulated for transdermal delivery.

$3.26
As of 12/06/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  USA
Country of incorporation:  USA
IPO date:  08/05/2015
Outstanding shares:  41,217,537
Average volume:  1,799,436
Market cap:   $131,483,943
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    98986X109
ISIN:        US98986X1090
Sedol:      BZ03R68
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.67
PS ratio:   0.00
Return on equity:   -48.43%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy